| 1RV1 | A:25-109; B:25-109; C:25-109 | CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR |
| 1T4E | A:16-111; B:16-111 | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH A BENZODIAZEPINE INHIBITOR |
| 1T4F | M:23-110 | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH AN OPTIMIZED P53 PEPTIDE |
| 1YCR | A:25-109 | MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 |
| 1Z1M | A:18-109 | NMR STRUCTURE OF UNLIGANDED MDM2 |
| 2AXI | A:23-114 | HDM2 IN COMPLEX WITH A BETA-HAIRPIN |
| 2GV2 | A:25-112 | MDM2 IN COMPLEX WITH AN 8-MER P53 PEPTIDE ANALOGUE |
| 2VYR | A:25-110; B:25-110; C:25-110; D:25-110 | STRUCTURE OF HUMAN MDM4 N-TERMINAL DOMAIN BOUND TO A SINGLE DOMAIN ANTIBODY |
| 3DAB | A:500-109; G:500-109; C:500-107; E:500-107 | STRUCTURE OF THE HUMAN MDMX PROTEIN BOUND TO THE P53 TUMOR SUPPRESSOR TRANSACTIVATION DOMAIN |
| 3FDO | A:22-111 | STRUCTURE OF HUMAN MDMX IN COMPLEX WITH HIGH AFFINITY PEPTIDE |
| 3FE7 | A:26-108 | CRYSTAL STRUCTURE OF HDMX BOUND TO THE P53-PEPTIDOMIMETIC AC-PHE-MET-AIB-PMP-TRP-GLU-AC3C-LEU-NH2 AT 1.35A |
| 3FEA | A:26-108 | CRYSTAL STRUCTURE OF HDMX BOUND TO THE P53-PEPTIDOMIMETIC AC-PHE-MET-AIB-PMP-6-CL-TRP-GLU-AC3C-LEU-NH2 AT 1.33A |
| 3G03 | A:25-111; C:26-108 | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH HIGH AFFINITY PEPTIDE |
| 3JZK | A:18-110 | CRYSTAL STRUCTURE OF MDM2 WITH CHROMENOTRIAZOLOPYRIMIDINE 1 |
| 3JZO | A:23-109 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE (PDI) |
| 3JZP | A:23-109 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDI6W) |
| 3JZQ | B:25-111; A:25-108 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDIQ) |
| 3JZR | A:16-112 | HUMAN MDM2 LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDI6W) |
| 3JZS | A:26-108 | HUMAN MDM2 LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDIQ) |
| 3LBJ | E:25-107 | STRUCTURE OF HUMAN MDMX PROTEIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR |
| 3LBK | A:26-110 | STRUCTURE OF HUMAN MDM2 PROTEIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR |
| 3LBL | E:19-110; C:19-110; A:17-110 | STRUCTURE OF HUMAN MDM2 PROTEIN IN COMPLEX WITH MI-63-ANALOG |
)
)